Xiaomi's Profit Rises on Smartphone and IoT Sales, Strong EV Margins
By Jiahui Huang
Xiaomi grew its net profit and revenue in the second quarter, posting solid smartphone sales, record-high revenue from its Internet-of-Things segment, and strong margins in its electric-vehicle business.
The Chinese maker of smartphones and other consumer electronics said Wednesday that net profit rose 39% from a year earlier to 5.10 billion yuan, equivalent to $714.6 million. That beat the 4.47 billion yuan estimated by analysts polled by FactSet.
After adjusting for share-based compensation and other items, the company's quarterly profit was 6.18 billion yuan, compared with 5.14 billion yuan a year earlier.
Revenue for the quarter rose 32% to 88.89 billion yuan, beating the FactSet-compiled estimate for 87.36 billion yuan.
Revenue from Xiaomi's smartphone business rose 27% to 46.52 billion yuan, while revenue from its IoT and lifestyle products segment, which includes tablets, television sets and laptops, rose 20% to 26.76 billion yuan.
The Beijing-based company generated 6.2 billion yuan of revenue from its EV business after launching its first electric car, the SU7, in late March.
Xiaomi's gross profit margin fell to 20.7% from 21.0% a year earlier, and from 22.3% the previous quarter.
Write to Jiahui Huang at jiahui.huang@wsj.com
(END) Dow Jones Newswires
August 21, 2024 06:15 ET (10:15 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks